Category
Darolutamide
Darolutamide
CAS Number
1297538-32-9
Molecular Formula
C₁₉H₁₉ClN₆O₂
Molecular Weight
398.85 g/mol
Synonym

N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;, N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide;

Keywords
High-Quality Pharmaceutical Reference Standards
Intermediates
Impurities
Metabolites.
Pharmaceutical Standards
Fine Chemicals
Slide_1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Darolutamide (CAS No. 1297538-32-9), with a Molecular Formula of C₁₉H₁₉ClN₆O₂ and Molecular Weight of 398.85 g/mol, is a nonsteroidal androgen receptor inhibitor used in the treatment of certain types of prostate cancer. Manasa Life Sciences, a pharmaceutical API reference standards manufacturer and supplier in India, offers Darolutamide API Analytical Reference Standard for oncology pharmaceutical research, API identification, assay determination, purity analysis, impurity profiling, related substances testing, analytical method development, and pharmaceutical quality control. This Darolutamide Reference Standard supports advanced analytical techniques, including HPLC, UHPLC, LC-MS/MS, NMR spectroscopy, FTIR analysis, and stability-indicating method validation, helping pharmaceutical laboratories assess the identity, purity, and quality of Darolutamide drug substances and formulations. As a Darolutamide API Reference Standard Supplier in India, Manasa Life Sciences serves API manufacturers, anticancer pharmaceutical companies, CROs, CDMOs, and analytical testing laboratories with Darolutamide pharmaceutical reference materials, oncology API analytical standards, HPLC reference standards, and anticancer drug quality control materials. Product-specific documentation, including Certificate of Analysis (COA), SDS/MSDS, chromatographic purity data, and spectral characterization reports, may be available upon request, subject to availability, supporting pharmaceutical analytical activities aligned with applicable ICH, USP, EP, and other relevant regulatory guidelines.